TY - JOUR
T1 - GliMR: Cross-Border Collaborations to Promote Advanced MRI Biomarkers for Glioma
AU - Clement, Patricia
AU - Booth, Thomas
AU - Borovečki, Fran
AU - Emblem, Kyrre E.
AU - Figueiredo, Patrícia
AU - Hirschler, Lydiane
AU - Jančálek, Radim
AU - Keil, Vera C.
AU - Maumet, Camille
AU - Özsunar, Yelda
AU - Pernet, Cyril
AU - Petr, Jan
AU - Pinto, Joana
AU - Smits, Marion
AU - Warnert, Esther A. H.
N1 - Funding Information:
We thank Prof. Dr. Eric Achten and Dr. Siri Fløgstad Svensson, Prof. Dr. Frederik Barkhof, Prof. Dr. Philip De Witt Hamer, and Dr. Niels Verburg for providing MR images of glioma patients, allowing us to create an overview of conventional and advanced MR modalities for glioma. The images provided by Prof. Radim Jančálek were acquired for research supported by the program INTER-EXCELLENCE, subprogram INTER-COST of the Ministry of Education, Youth and Sports CR, Grant No. LTC20027.
Publisher Copyright:
© 2020, The Author(s).
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2021/4
Y1 - 2021/4
N2 - Purpose: There is an annual incidence of 50,000 glioma cases in Europe. The optimal treatment strategy is highly personalised, depending on tumour type, grade, spatial localization, and the degree of tissue infiltration. In research settings, advanced magnetic resonance imaging (MRI) has shown great promise as a tool to inform personalised treatment decisions. However, the use of advanced MRI in clinical practice remains scarce due to the downstream effects of siloed glioma imaging research with limited representation of MRI specialists in established consortia; and the associated lack of available tools and expertise in clinical settings. These shortcomings delay the translation of scientific breakthroughs into novel treatment strategy. As a response we have developed the network “Glioma MR Imaging 2.0” (GliMR) which we present in this article. Methods: GliMR aims to build a pan-European and multidisciplinary network of experts and accelerate the use of advanced MRI in glioma beyond the current “state-of-the-art” in glioma imaging. The Action Glioma MR Imaging 2.0 (GliMR) was granted funding by the European Cooperation in Science and Technology (COST) in June 2019. Results: GliMR’s first grant period ran from September 2019 to April 2020, during which several meetings were held and projects were initiated, such as reviewing the current knowledge on advanced MRI; developing a General Data Protection Regulation (GDPR) compliant consent form; and setting up the website. Conclusion: The Action overcomes the pre-existing limitations of glioma research and is funded until September 2023. New members will be accepted during its entire duration.
AB - Purpose: There is an annual incidence of 50,000 glioma cases in Europe. The optimal treatment strategy is highly personalised, depending on tumour type, grade, spatial localization, and the degree of tissue infiltration. In research settings, advanced magnetic resonance imaging (MRI) has shown great promise as a tool to inform personalised treatment decisions. However, the use of advanced MRI in clinical practice remains scarce due to the downstream effects of siloed glioma imaging research with limited representation of MRI specialists in established consortia; and the associated lack of available tools and expertise in clinical settings. These shortcomings delay the translation of scientific breakthroughs into novel treatment strategy. As a response we have developed the network “Glioma MR Imaging 2.0” (GliMR) which we present in this article. Methods: GliMR aims to build a pan-European and multidisciplinary network of experts and accelerate the use of advanced MRI in glioma beyond the current “state-of-the-art” in glioma imaging. The Action Glioma MR Imaging 2.0 (GliMR) was granted funding by the European Cooperation in Science and Technology (COST) in June 2019. Results: GliMR’s first grant period ran from September 2019 to April 2020, during which several meetings were held and projects were initiated, such as reviewing the current knowledge on advanced MRI; developing a General Data Protection Regulation (GDPR) compliant consent form; and setting up the website. Conclusion: The Action overcomes the pre-existing limitations of glioma research and is funded until September 2023. New members will be accepted during its entire duration.
KW - Advanced MRI
KW - COST action
KW - Glioma
KW - Multi-disciplinary
KW - Networking
KW - Translational research
UR - http://www.scopus.com/inward/record.url?scp=85097160155&partnerID=8YFLogxK
U2 - 10.1007/s40846-020-00582-z
DO - 10.1007/s40846-020-00582-z
M3 - Review article
C2 - 33293909
VL - 41
SP - 115
EP - 125
JO - Journal of Medical and Biological Engineering
JF - Journal of Medical and Biological Engineering
SN - 1609-0985
IS - 2
ER -